Dr. Wilson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Room 4n115 Bldg 10
9000 Rockville Pike
Bethesda, MD 20892Phone+1 240-760-6092- Is this information wrong?
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1984 - 1987
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1981 - 1984
Stanford University School of MedicineClass of 1981
Certifications & Licensure
CA State Medical License 2019 - 2025
WV State Medical License 1985 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Start of enrollment: 1993 May 08
- Treatment and Natural History Study of Lymphomatoid Granulomatosis Start of enrollment: 1995 May 05
- EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma Start of enrollment: 1997 Jan 08
- Join now to see all
Publications & Presentations
PubMed
- Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.Rahul Lakhotia, Kieron Dunleavy, Jeremy S Abramson, Brian K Link, Bayard L Powell, Christopher Melani, Andrea N Lucas, Seth M Steinberg, Jonathan W Friedberg, Brad S K...> ;Blood Advances. 2023 Sep 26
- 9 citationsClinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial.Peter W M Johnson, Sriram Balasubramanian, Brendan Hodkinson, S Martin Shreeve, Steven Sun, Srimathi Srinivasan, Andrew J Steele, Jessica Vermeulen, Laurie H Sehn, Wyn...> ;Blood Advances. 2023 May 23
- 1 citationsInterferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an ...Christopher Melani, Kennichi Dowdell, Stefania Pittaluga, Kieron Dunleavy, Mark Roschewski, Joo Y Song, Sara Calattini, Jun-Ichi Kawada, David A Price, Pratip K Chatto...> ;The Lancet. Haematology. 2023 May 1
- Join now to see all
Journal Articles
- End-of-Treatment and Serial PET Imaging Has Prognostic Value and Clinical Utility in Primary Mediastinal B-cell Lymphoma Following Dose-Adjusted EPOCH-R - Response to ...Mark Roschewski, Wyndham H Wilson, Christopher Melani, Haematologica
- A Multiprotein Supercomplex Controlling Oncogenic Signalling in LymphomaMaryknoll M Palisoc, Lisa M Rimsza, Stephen M Hewitt, Wyndham H Wilson, Matthias Holdhoff, Fayez Estephan, Nature
Abstracts/Posters
- Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RRWyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix TrialWyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 TrialWyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term D...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Ibrutinib Add-on 'Almost Certainly' Saves Lives in DLBCLNovember 4th, 2021- Global Trial Eliminates Drugs, Pivots to New OnesOctober 23rd, 2020
- Cancer Researchers Cross over to COVID-19 Clinical TrialsOctober 20th, 2020
- Join now to see all
Grant Support
- Phase I And II Study Of BCL Family Inhibitors In LymphomaNational Cancer Institute2011
- Randomized Phase II Study Of Borteozmibepoch-R In Mantle Cell LymphomaNational Cancer Institute2010–2011
- Phase III Study Of R-CHOP V Da-Epoch-R With MicroarrayNational Cancer Institute2010–2011
- Phase II Study Of Flavopiridol In Mantle Cell Lymphoma And DlbclNational Cancer Institute2010–2011
- Phase I Study Of Bortezomib And Da-Epoch-R With Microarray In DlbclNational Cancer Institute2010–2011
- Lymphoma StudiesNational Cancer Institute2010–2011
- BCR Signaling In ABC DlbclNational Cancer Institute2010–2011
- Phase III Study Of Bcl-Family Inhibitors In LymphomaNational Cancer Institute2010
- Lymphoma StudiesDivision Of Clinical Sciences - Nci2009
- Randomized Phase II Study Of Borteozmibepoch-R In Mantle Cell LymphomaDivision Of Basic Sciences - Nci2009
- Phase III Study Of R-CHOP V Da-Epoch-R With MicroarrayDivision Of Basic Sciences - Nci2009
- Phase II Study Of Flavopiridol In Mantle Cell Lymphoma And DlbclDivision Of Basic Sciences - Nci2009
- Phase I/II Study Of Bcl-Family Inhibitors In LymphomaDivision Of Basic Sciences - Nci2009
- Phase I Study Of Bortezomib And Da-Epoch-R With Microarray In DlbclDivision Of Basic Sciences - Nci2009
- Randomized Phase II Study Of Borteozmibepoch-R In Mantle Cell LymphomaNational Cancer Institute2007–2008
- Phase III Study Of R-CHOP V Da-Epoch-R With MicroarrayNational Cancer Institute2007–2008
- Phase III Study Of Bcl-Family Inhibitors In LymphomaNational Cancer Institute2007–2008
- Phase II Study Of Flavopiridol In Mantle Cell Lymphoma And DlbclNational Cancer Institute2007–2008
- Phase I Study Of Bortezomib And Da-Epoch-R With Microarray In DlbclNational Cancer Institute2007–2008
- Lymphoma StudiesNational Cancer Institute2007–2008
- Randomized Phase II Study Of Borteozmibepoch-R In MantleDivision Of Basic Sciences - Nci2006
- Phase III Study Of R-CHOP V Da-Epoch-R With MicroarrayDivision Of Basic Sciences - Nci2006
- Phase III Study Of Bcl-Family Inhibitors In LymphomaDivision Of Basic Sciences - Nci2006
- Phase II Study Of Flavopiridol In Mantle Cell Lymphoma ADivision Of Basic Sciences - Nci2006
- Phase I Study Of Bortezomib And Da-Epoch-R With MicroarrDivision Of Basic Sciences - Nci2006
- Lymphoma StudiesDivision Of Clinical Sciences - Nci1996–2006
Hospital Affiliations
NIH Clinical CenterBethesda, Maryland
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
